Eric J. Feldman

Learn More
We wish to express our continuing appreciation to the U.S. Environmental Protection Agency for its financial support of this project, and especially to James Horne, who provided invaluable advice as well as project oversight; to the staff of all the participating facilities and state and federal agencies who contributed their time and data to this project;(More)
PURPOSE Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro. METHODS Adults with relapsed/refractory acute myeloid leukemia (n = 14) and acute lymphoid leukemia (n = 6) were(More)
At present, there is no method available to predict response to farnesyltransferase inhibitors (FTIs). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib in older adults with previously untreated acute myeloid leukemia (AML). The RASGRP1/APTX gene expression ratio was found to predict response to(More)
Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a majority of patients had antecedent myelodysplastic(More)
Standard guidelines for cancer pain treatment routinely recommend training patients to reduce barriers to pain relief, use medications appropriately, and communicate their pain-related needs. Methods are needed to reduce professional time required while achieving sustained intervention effectiveness. In a multisite, randomized controlled trial, this study(More)
The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergistically enhanced etoposide-induced antiproliferative effects in(More)
leukemia and elderly patients with previously untreated acute myelogenous A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk (4217 articles) Neoplasia (3667 articles) Clinical Trials and Observations Articles on similar topics can be found in the following Blood collections Information about subscriptions and ASH membership may be(More)
inhibitor tipifarnib in acute myeloid leukemia A two-gene classifier for predicting response to the farnesyltransferase (3667 articles) Clinical Trials and Observations Articles on similar topics can be found in the following Blood collections Information about subscriptions and ASH membership may be found online at: digital object identifier (DOIs) and(More)
OBJECTIVES To study relationships between median wrist and forearm sonographic measurements and median nerve conduction studies. METHODS The study population consisted of a prospective convenience sample of healthy adults. Interventions included high-resolution median nerve sonography and median motor and sensory nerve conduction studies. Main outcome(More)
etoposide farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with myelogenous leukemia: A preclinical and phase I trial of the Active oral regimen for elderly adults with newly diagnosed acute (883 articles) Myeloid Neoplasia (1597 articles) Free Research Articles (3667 articles) Clinical Trials and Observations Articles on similar(More)
  • 1